The cytokeratin-positive immunoreactivity in the tumor cells was demonstrated in all the epithelial tumor cases by IHC, and the vimentin-positive immunoreactivity in the tumor cells was also demonstrated in the mesenchymal tumor and melanocytic tumor cases by IHC (Table 1). This evidence concerns the gene VIM and mesenchymal cell neoplasm.